ReviewClinical and translational science2017
The Role of Public-Private Partnerships in Catalyzing the Critical Path.
Review in Clinical and translational science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- National Institute for Pharmaceutical Technology and Education Special Issue.Pharmaceutical research · 2026Article
- Lupus ABC spearheading a new era of collaboration to advance lupus drug development.Nature reviews. Rheumatology · 2025Article
- Challenges and opportunities of acquiring cortical recordings for chronic adaptive deep brain stimulation.Nature biomedical engineering · 2025Review
- Can Lp(a) become the next A1C? A case for digital health management tools to overcome inertia to Lipoprotein (a) testing.Frontiers in cardiovascular medicine · 2025Article
- Transforming Drug Development for Neurological Disorders: Proceedings from a Multidisease Area Workshop.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023Article
- Disease progression joint model predicts time to type 1 diabetes onset: Optimizing future type 1 diabetes prevention studies.CPT: pharmacometrics & systems pharmacology · 2023Article
- Identifying and characterising sources of variability in digital outcome measures in Parkinson's disease.NPJ digital medicine · 2022Article
- Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science.Digital biomarkers · 2020Review
- Accelerating Therapeutics for Opportunities in Medicine: A Paradigm Shift in Drug Discovery.Frontiers in pharmacology · 2020Article
- New Frontiers in Parkinson's Disease: From Genetics to the Clinic.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.